| 张文杰,丁钐,潘琦.阻塞性睡眠呼吸暂停的药物治疗新视角:聚焦肠促胰素[J].中国临床保健杂志,2025,28(6):763-768. |
| 阻塞性睡眠呼吸暂停的药物治疗新视角:聚焦肠促胰素 |
| A new perspective on drug therapy for obstructive sleep apnea:focusing on incretin |
| 投稿时间：2025-11-06 |
| DOI：10.3969/J.issn.1672-6790.2025.06.008 |
| 中文关键词: 睡眠呼吸暂停,阻塞性 肠促胰素类 连续气道正压通气 综述 |
| 英文关键词: Sleep apnea,obstructive Incretins Continuous positive airway pressure Review 〖FL |
| 基金项目:国家科技重大专项(2024ZD0531900,2024ZD0531905)；北京医院指南专项(BJ-2025-209) |
|
| 摘要点击次数: 37 |
| 全文下载次数: 25 |
| 中文摘要: |
| 阻塞性睡眠呼吸暂停(OSA)的发病率逐年升高,已成为全球性的健康挑战。目前,中重度OSA的一线治疗方法为持续气道正压通气,虽然有效但存在依从性等问题。近年来,以胰高血糖素样肽-1(GLP-1)受体激动剂及葡萄糖依赖性促胰岛素释放多肽(GIP)/GLP-1受体激动剂为代表的肠促胰素类药物,为OSA的治疗提供了全新视角。该类药物不仅能通过调节食欲和摄食行为显著减重这一核心机制改善上气道解剖结构,临床证据更显示其具有抗炎、改善能量代谢、调节脂肪分布等多重非减重效应,能全方位改善OSA病理生理进程,有效减少睡眠呼吸暂停事件。本文旨在综述肠促胰素类药物治疗OSA的最新临床研究进展,讨论多重效应及其面临的挑战与应用前景。 |
| 英文摘要: |
| Obstructive Sleep Apnea (OSA) is an increasingly prevalent global health burden.While continuous positive airway pressure remains the traditional first-line therapy,its efficacy is often limited by suboptimal adherence.Recently,incretin-based therapies,including GLP-1 receptor agonists (GLP-1RA) and dual GIP/GLP-1RA,have emerged as a promising new pharmacologic strategy for OSA management.These agents primarily improve upper airway anatomy through significant weight loss mediated by appetite and feeding regulation.Critically,mounting clinical evidence suggests that these drugs also exert potent pleiotropic effects independent of weight loss,such as anti-inflammation,enhancement of energy metabolism,and favorable fat distribution remodeling.This multifaceted approach targets the complex pathophysiology of OSA,leading to an effective reduction in apnea events.This article reviews the latest clinical advances and key evidence supporting the use of incretin-based drugs for OSA,summarizes their diverse mechanisms of action,and discusses the future challenges and clinical application prospects of this rapidly evolving field. |
|
查看全文
|
| 关闭 |
|
|
|